Patrik Pipkorn

Dr. Patrik Pipkorn


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
RURavindra Uppaluri
Ravindra Uppaluri
KCKatie M. Campbell
Katie M. Campbell
AEAnn Marie Egloff
Ann Marie Egloff
PZPaul Zolkind
Paul Zolkind
ZSZachary L. Skidmore
Zachary L. Skidmore
DADouglas R. Adkins
Douglas R. Adkins
Purpose: Pembrolizumab improved survival in patients with recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC). The aims of this study were to determine if pembrolizumab would be safe, result in pathologic tumor response (pTR), and lower the relapse rate in patients with resectable human papillomavirus (HPV)–unrelated HNSCC. Patients and Methods: Neoadjuvant pembrolizumab (200 mg) was administered and followed 2 to 3 weeks later by surgical tumor ablation. Postoperative (chemo)radiation was planned. Patients with high-risk pathology (positive margins and/or extranodal extension) received adjuvant pembrolizumab. pTR was quantified as the proportion of the resection bed with tumor necrosis, keratinous debris, and giant cells/histiocytes: pTR-0 (<10%), pTR-1 (10%–49%), and pTR-2 (≥50%). Coprimary endpoints were pTR-2 among all patients and 1-year relapse rate in patients with high-risk pathology (historical: 35%). Correlations of baseline PD-L1 and T-cell infiltration with pTR were assessed. Tumor clonal dynamics were evaluated (ClinicalTrials.gov NCT02296684). Results: Thirty-six patients enrolled. After neoadjuvant pembrolizumab, serious (grades 3–4) adverse events and unexpected surgical delays/complications did not occur. pTR-2 occurred in eight patients (22%), and pTR-1 in eight other patients (22%). One-year relapse rate among 18 patients with high-risk pathology was 16.7% (95% confidence interval, 3.6%–41.4%). pTR ≥10% correlated with baseline tumor PD-L1, immune infiltrate, and IFNγ activity. Matched samples showed upregulation of inhibitory checkpoints in patients with pTR-0 and confirmed clonal loss in some patients. Conclusions: Among patients with locally advanced, HPV-unrelated HNSCC, pembrolizumab was safe, and any pathologic response was observed in 44% of patients with 0% pathologic complete responses. The 1-year relapse rate in patients with high-risk pathology was lower than historical.

29 September 2023 in Science Immunology
Verified
Journal Article
Closed access
GOGiacomo Oliveira
Giacomo Oliveira
AEAnn Marie Egloff
Ann Marie Egloff
AAAlexander B. Afeyan
Alexander B. Afeyan
JWJacquelyn O. Wolff
Jacquelyn O. Wolff
ZZZexiang Zeng
Zexiang Zeng
RURavindra Uppaluri
Ravindra Uppaluri
About 50% of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) experience recurrences after definitive therapy. The presurgical administration of anti–programmed cell death protein 1 (PD-1) immunotherapy results in substantial pathologic tumor responses (pTR) within the tumor microenvironment (TME). However, the mechanisms underlying the dynamics of antitumor T cells upon neoadjuvant PD-1 blockade remain unresolved, and approaches to increase pathologic responses are lacking. In a phase 2 trial (NCT02296684), we observed that 45% of patients treated with two doses of neoadjuvant pembrolizumab experienced marked pTRs (≥50%). Single-cell analysis of 17,158 CD8 + T cells from 14 tumor biopsies, including 6 matched pre-post neoadjuvant treatment, revealed that responding tumors had clonally expanded putative tumor-specific exhausted CD8 + tumor-infiltrating lymphocytes (TILs) with a tissue-resident memory program, characterized by high cytotoxic potential (CTX + ) and ZNF683 expression, within the baseline TME. Pathologic responses after 5 weeks of PD-1 blockade were consistent with activation of preexisting CTX + ZNF683 + CD8 + TILs, paralleling loss of viable tumor and associated tumor antigens. Response was associated with high numbers of CD103 + PD-1 + CD8 + T cells infiltrating pretreatment lesions, whereas revival of nonexhausted persisting clones and clonal replacement were modest. By contrast, nonresponder baseline TME exhibited a relative absence of ZNF683 + CTX + TILs and subsequent accumulation of highly exhausted clones. In HNSCC, revival of preexisting ZNF683 + CTX + TILs is a major mechanism of response in the immediate postneoadjuvant setting.

1 September 2020 in American Journal of Otolaryngology
Verified
Journal Article
Closed access
SCStephanie Y. Chen
Stephanie Y. Chen
SMSean Massa
Sean Massa
AMAngela L. Mazul
Angela L. Mazul
DKDorina Kallogjeri
Dorina Kallogjeri
LYLauren Yaeger
Lauren Yaeger
PPPatrik Pipkorn
Patrik Pipkorn

20 April 2017 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
JZJoseph Zenga
Joseph Zenga
JSJasmina Suko
Jasmina Suko
DKDorina Kallogjeri
Dorina Kallogjeri
PPPatrik Pipkorn
Patrik Pipkorn
BNBrian Nussenbaum
Brian Nussenbaum
RJRyan S. Jackson
Ryan S. Jackson

11 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
ZQZongtai Qi
Zongtai Qi
YLYating Liu
Yating Liu
MMMichael Mints
Michael Mints
RMRiley Mullins
Riley Mullins
RSReilly Sample
Reilly Sample
Sidharth PuramSidharth Puram
Sidharth Puram
Complexities in cell-type composition have rightfully led to skepticism and caution in the interpretation of bulk transcriptomic analyses. Recent studies have shown that deconvolution algorithms can be utilized to computationally estimate cell-type proportions from the gene expression data of bulk blood samples, but their performance when applied to tumor tissues, including those from head and neck, remains poorly characterized. Here, we use single-cell data (~6000 single cells) collected from 21 head and neck squamous cell carcinoma (HNSCC) samples to generate cell-type-specific gene expression signatures. We leverage bulk RNA-seq data from >500 HNSCC samples profiled by The Cancer Genome Atlas (TCGA), and using single-cell data as a reference, apply two newly developed deconvolution algorithms (CIBERSORTx and MuSiC) to the bulk transcriptome data to quantitatively estimate cell-type proportions for each tumor in TCGA. We show that these two algorithms produce similar estimates of constituent/major cell-type proportions and that a high T-cell fraction correlates with improved survival. By further characterizing T-cell subpopulations, we identify that regulatory T-cells (Tregs) were the major contributor to this improved survival. Lastly, we assessed gene expression, specifically in the Treg population, and found that TNFRSF4 (Tumor Necrosis Factor Receptor Superfamily Member 4) was differentially expressed in the core Treg subpopulation. Moreover, higher TNFRSF4 expression was associated with greater survival, suggesting that TNFRSF4 could play a key role in mechanisms underlying the contribution of Treg in HNSCC outcomes.

8 October 2019 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
JGJennifer H. Gross
Jennifer H. Gross
PVPeter M. Vila
Peter M. Vila
LSLaura Simon
Laura Simon
ZRZain H. Rizvi
Zain H. Rizvi
JZJoseph Zenga
Joseph Zenga
PPPatrik Pipkorn
Patrik Pipkorn